NCT00409409View on ClinicalTrials.gov

Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Children Suffering From Grass Pollen Rhinoconjunctivitis

PHASE3CompletedINTERVENTIONAL
Enrollment

278

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

September 30, 2007

Study Completion Date

September 30, 2007

Conditions
Allergy
Interventions
DRUG

300 IR grass pollen allergen extract tablet

One sublingual tablet daily during 4 months before pollen season and during pollen season

DRUG

Placebo tablet

One sublingual tablet daily during 4 months before pollen season and during pollen season

Trial Locations (1)

Unknown

Charité - Campus Virchow Klinikum, Berlin

Sponsors

Lead Sponsor

Stallergenes Greer
All Listed Sponsors
lead

Stallergenes Greer

INDUSTRY

NCT00409409 - Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Children Suffering From Grass Pollen Rhinoconjunctivitis | Biotech Hunter | Biotech Hunter